Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.70
+$0.58 · +5.22%
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Previous close
$11.70
+$0.58 · +5.22%
Regular session · ET · Market data may be delayed.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Day range
Current $11.70
52-week range
Current $11.70
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
68
Bullish
Risk
53
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Day range
Current $11.70
52-week range
Current $11.70
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 68.56M USD | 74.21M USD | 86.18M USD | 1.62B USD | 1.1B USD |
| Cost of goods sold | 11.71M USD | 15.4M USD | 22.22M USD | 161.81M USD | 71.68M USD |
| Gross profit | 56.85M USD | 58.8M USD | 63.96M USD | 1.45B USD | 1.02B USD |
| Research and development | 432.8M USD | 463.19M USD | 550.92M USD | 467.87M USD | 442.2M USD |
| Selling, general, and administrative | 92.07M USD | 119.03M USD | 174.05M USD | 153.05M USD | 160.79M USD |
| Operating expenses | 524.87M USD | 582.22M USD | 724.97M USD | 620.92M USD | 602.99M USD |
| Interest income | 40.24M USD | 71.81M USD | 86.99M USD | 28.09M USD | 439K USD |
| Depreciation and amortization | 11.68M USD | 14.56M USD | 19.45M USD | 15.49M USD | 11.98M USD |
| Operating income | −468.02M USD | −523.42M USD | −661.01M USD | 833.07M USD | 420.75M USD |
| Net income | −437.99M USD | −521.96M USD | −615.06M USD | 515.84M USD | 528.58M USD |
Company facts updated Oct 11, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI53.02M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM39.95M0.05%78.74B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB38.19M0.02%185.3B USD0.03%$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI28.7M0.29%9.87B USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK21.88M0.05%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF15.48M0.02%95.4B USD0.05%$235+0.80%
Dimensional - US Small Cap ETFDFAS13.23M0.04%33.87B USD0.31%$78.35+0.32%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM12.96M0.08%15.84B USD0.03%$53.45+0.17%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
